Truist Financial Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $18.00

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) had its target price lowered by equities researchers at Truist Financial from $21.00 to $18.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. Truist Financial's price objective points to a potential upside of 288.35% from the company's current price.

Other equities analysts also recently issued reports about the stock. Bank of America decreased their price target on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Brookline Capital Management initiated coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a "buy" rating and a $17.00 price target on the stock. Wedbush restated an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday. Finally, Morgan Stanley cut their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $19.30.

Y-mAbs Therapeutics Trading Down 6.6 %

Shares of NASDAQ:YMAB traded down $0.33 during trading on Wednesday, reaching $4.64. 195,646 shares of the stock were exchanged, compared to its average volume of 467,754. Y-mAbs Therapeutics has a 12 month low of $4.25 and a 12 month high of $18.19. The stock has a 50-day moving average price of $6.46 and a 200-day moving average price of $10.62. The firm has a market cap of $207.60 million, a PE ratio of -8.58 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter last year, the firm earned ($0.02) earnings per share. On average, sell-side analysts expect that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of institutional investors have recently modified their holdings of YMAB. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Y-mAbs Therapeutics in the third quarter valued at about $44,000. KLP Kapitalforvaltning AS acquired a new position in Y-mAbs Therapeutics during the 4th quarter worth approximately $46,000. ProShare Advisors LLC acquired a new position in Y-mAbs Therapeutics during the 4th quarter worth approximately $99,000. Intech Investment Management LLC bought a new position in Y-mAbs Therapeutics in the 3rd quarter valued at approximately $133,000. Finally, Wells Fargo & Company MN boosted its position in Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock valued at $137,000 after buying an additional 6,131 shares in the last quarter. Institutional investors and hedge funds own 70.85% of the company's stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.